6:07 PM
Oct 22, 2012
 |  BC Extra  |  Company News

Alnylam grants Genzyme Asian rights for ALN-TTR program

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) granted Genzyme Corp. exclusive rights in Japan and other Asia-Pacific countries to develop and commercialize RNAi therapeutics for transthyretin (TTR). The deal includes two products for TTR-mediated amyloidosis: IV ALN-TTR02, in Phase II testing, and subcutaneous ALN-TTRsc, in preclinical testing. Alnylam plans to submit an IND to FDA...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >